

CytoCell

Blood cancers genetic testing



Table 1 CytoCell® products that support ALL testing [1,2]

Cat. No.	Product name	Label	Status
LPH 031	PDGFRB Breakapart Probe	● ●	IVDD
CE-LPH 007	BCR/ABL (ABL1) Translocation, Dual Fusion Probe	● ●	IVDR
LPH 012	TEL/AML1 (ETV6/RUNX1) Translocation, Dual Fusion Probe	● ●	IVDD
CE-LPH 013	MLL (KMT2A) Breakapart Probe	● ●	IVDR
LPH 080	E2A (TCF3)/PBX1 <i>Plus</i> Translocation, Dual Fusion Probe	● ● ●	IVDD

Table 2 CytoCell® products that support AML testing [3,4]

Cat. No.	Product name	Label	Status
LPH 095	Del(5q) <i>Plus</i> Deletion Probe	● ● ●	IVDD
LPS 037	P53 (TP53) Deletion Probe	● ●	IVDD
CE-LPH 036	EVI1 (MECOM) Breakapart Probe	● ● ●	IVDR
CE-LPH 089	CBFB Breakapart Probe	● ●	IVDR
CE-LPH 026	AML1/ETO (RUNX1/RUNX1T1) Translocation, Dual Fusion Probe	● ●	IVDR
CE-LPH 064	FAST PML/RAR α (RARA) Translocation, Dual Fusion Probe	● ●	IVDR
CE-LPH 038	BCR/ABL (ABL1) <i>Plus</i> Translocation, Dual Fusion Probe	● ● ●	IVDR

Table 3 CytoCell® products that support MM testing [5]

Cat. No.	Product name	Label	Status
LPS 027	MYC Breakapart Probe	● ●	IVDD
LPS 037	P53 (TP53) Deletion Probe	● ●	IVDD
CE-LPH 039	CKS1B/CDKN2C (P18) Amplification/Deletion Probe	● ●	IVDR
LPH 077	IGH/MAFB <i>Plus</i> Translocation, Dual Fusion Probe	● ●	IVDD
LPH 075	IGH/CCND3 <i>Plus</i> Translocation, Dual Fusion Probe	● ●	IVDD

Table 4 CytoCell® products that support CLL testing [6,7,8,9]

Cat. No.	Product name	Label	Status
LPH 016	MYB Deletion Probe	● ●	IVDD
LPH 069	Alpha Satellite 12 <i>Plus</i> Probe	●	IVDD
LPH 006	13q14.3 Deletion Probe	● ●	IVDD
LPH 011	ATM Deletion Probe	● ●	IVDD
LPH 071	IGH/BCL2 <i>Plus</i> Translocation, Dual Fusion Probe	● ●	IVDD
LPH 070	IGH <i>Plus</i> Breakapart Probe	● ●	IVDD
LPS 037	P53 (TP53) Deletion Probe	● ●	IVDD

Table 5 CytoCell® products that support blood cancer research

Cat. No.	Product name	Label	Status
MPH51700	PDGFRB/CSF1R Breakapart Probe	● ● ●	RUO
MPH51680	ABL2 Breakapart/TP53 Deletion Probe	● ● ●	RUO
MPD2680	JAK2 Breakapart Probe	● ●	RUO
MPH22100	MLL/AFF1 Breakapart/Dual Fusion Probe	● ● ●	RUO
MPH51690	CRLF2/P2RY8/IGH <i>Plus</i> Deletion/Breakapart Probe	● ● ●	RUO
MPH4290	NUP214/DEK Dual Fusion Probe	● ●	RUO
MPH21490	MLL/MLLT3 Breakapart/Dual Fusion Probe	● ● ●	RUO
MPH13880	Del(7q) <i>Plus</i> Deletion Probe	● ● ●	RUO
MPH2920	15cen/9qhet/5p15.31 Enumeration Probe	● ● ●	RUO
MPD52820	IGH/FGFR3 Breakapart/Dual Fusion v2 Probe	● ● ●	RUO
MPD22710	IGH/CCND1/MAF Dual Fusion v2 Probe	● ● ●	RUO

Table 6 CytoCell® accessories

Cat. No.	Product name
PCA 005	Rubber Solution Glue 15g
PCN 002	Slide Surface Thermometer (4-pack)
PCN 003	Mounting Medium (10ml)
PCN 004	Hybridisation Chamber
PCN 007	24 Square Template Slides (x72)
PCN 008	8 Square Template Slides (x72)
PCN 009	Porcelain Wash Jars (2-pack)
PCN 010	MultiSpot 8 Square Glass Platform (x100)

Glossary

ALL: Acute lymphoblastic leukaemia; **AML:** Acute myeloid leukaemia; **MM:** Multiple myeloma; **CLL:** Chronic lymphocytic leukaemia

References

[1] Heyman M. (2018): ALLTogether1 – A Treatment study protocol of the ALLTogether Consortium for children and young adults (0-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL). [Clinical trials](#).

[2] Moorman A. et al. (2021): Summary of the recommendations from the ALLTogether Genetics group for the genetic screening of patients treated on the ALLTogether1 Protocol.

[3] Heuser M. et al. (2020): Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 31.6: 697–712.

[4] Döhner H. et al. (2022): Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood, The Journal of the American Society of Hematology* 140.12: 1345–1377.

[5] Rajkumar, S. Vincent (2020): Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. *American journal of hematology* 95.5: 548–567.

[6] Eichhorst B. et al. (2021): Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 32.1: 23–33.

[7] Hallek M. et al. (2018): iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood, The Journal of the American Society of Hematology* 131.25: 2745–2760.

[8] Döhner H. et al. (2000): Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med*. Dec 28;343 (26):1910–6.

[9] Hampel P.J. et al. (2022): Chronic lymphocytic leukemia treatment algorithm. *Blood Cancer J*. 12, 161.

OGT's CytoCell® IVDR-certified range of fluorescence *in situ* hybridisation (FISH) probe kits are *in vitro* diagnostic (IVD) medical devices for the detection of prenatal trisomy 13 & 21 and acquired cancer-related chromosome alterations. They have been CE-marked under Regulation (EU) 2017/746 (IVDR) as Class C IVD medical devices for laboratory professional use only and are not intended for use as a standalone diagnostic or companion diagnostic. Refer to each individual FISH probe kit's Instructions for Use for their specific Intended Purpose, Indications, and Limitations.

CytoCell®: Product availability may vary from country to country and is subject to varying regulatory requirements. Contact your local representatives for availability. CytoCell® is registered trademark of CytoCell Limited. For Research Use Only. Not for diagnostic procedures.

Distributor EMEA: Sysmex Europe SE · www.sysmex-europe.com
 Manufacturer CytoCell®: CytoCell Limited · www.ogt.com
 You will find your local Sysmex representative's address under www.sysmex-europe.com/contacts

www.sysmex-europe.com/cytoCell